zepbound eli lilly - Search News

Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

Seeking Alpha · 1d

Eli Lilly Stock's Correction Brings Opportunity

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

24/7 Wall St · 13d

Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and currently trading at $756.99. The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years,

Zacks.com on MSN · 2d

Eli Lilly (LLY) Stock Drops Despite Market Gains: Important Facts to Note

Eli Lilly (LLY) closed the latest trading day at $804.99, indicating a -0.39% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.92%. At the same time,

Investing.com on MSN · 3d

Eli Lilly's SWOT analysis: stock poised for growth amid challenges

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a landscape of robust demand for its groundbreaking diabetes and obesity treatments,

Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

FiercePharma3d

Gearing up to challenge Lilly in obesity, Kailera picks Zepbound brand leader as new commercial chief

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

Eli Lilly: Market Overreacted

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble?

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, ...

The Pharma Letter2d

Kailera snags Lilly’s Zepbound brand leader

Newly-launched obesity company Kailera Therapeutics has announced the appointment of Jamie Coleman as chief commercial ...

The Motley Fool12d

Eli Lilly Missed Sales Expectations Again. Should Investors Be Worried?

Eli Lilly's stock price finished Jan. 16 down 21% from a peak it set last September. The sales trajectory of Mounjaro and Zepbound tapered off in the second half of 2024. An oral weight-loss ...

Hosted on MSN2d

What Does the Future Hold for Eli Lilly?

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Eli Lilly & Co. stock outperforms competitors on strong trading day

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results